madopar hart hylki 100 mg og 25 mg
roche pharmaceuticals a/s - benserazidum hýdróklóríð; levodopum inn - hart hylki - 100 mg og 25 mg
madopar hart hylki 50 mg og 12,5 mg
roche pharmaceuticals a/s - benserazidum hýdróklóríð; levodopum inn - hart hylki - 50 mg og 12,5 mg
madopar tafla 125 mg
roche pharmaceuticals a/s - benserazidum hýdróklóríð; levodopum inn - tafla - 125 mg
madopar depot hart forðahylki 100 mg/25 mg
roche pharmaceuticals a/s - benserazidum hýdróklóríð; levodopum inn - hart forðahylki - 100 mg/25 mg
madopar quick lausnartafla 100 mg/25 mg
roche pharmaceuticals a/s - levodopum inn; benserazidum hýdróklóríð - lausnartafla - 100 mg/25 mg
madopar quick lausnartafla 50 mg/12,5 mg
roche pharmaceuticals a/s - levodopum inn; benserazidum hýdróklóríð - lausnartafla - 50 mg/12,5 mg
noradrenalina normon innrennslisþykkni, lausn 1 mg/ml
laboratorios normon, s.a. - noradrenalinum tartrat (norepinephrinum tartrat) - innrennslisþykkni, lausn - 1 mg/ml
upstaza
ptc therapeutics international limited - eladocagene exuparvovec - aminósýra efnaskipti, innfæddir villur - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.
sinemet 12,5/50 tafla 12,5 mg/50 mg
n.v. organon* - carbidopum inn; levodopum inn - tafla - 12,5 mg/50 mg
sinemet 25/100 tafla 25 mg/100 mg
n.v. organon* - levodopum inn; carbidopum inn - tafla - 25 mg/100 mg